Oncternal Therapeutics, Inc. Banner Image

Oncternal Therapeutics, Inc.

  • Ticker ONCT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Oncternal Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in San Diego, California
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonalMore antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer.
4.8 / 5.0 (144)

Oncternal Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 144 reviews.

Oncternal Therapeutics, Inc.

Most Recent Annual Report

Oncternal Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Oncternal Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!